Compare GRC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | NUVB |
|---|---|---|
| Founded | 1933 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1994 | N/A |
| Metric | GRC | NUVB |
|---|---|---|
| Price | $61.25 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 124.9K | ★ 4.5M |
| Earning Date | 04-23-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $682,389,000.00 | N/A |
| Revenue This Year | $6.62 | $190.15 |
| Revenue Next Year | $4.66 | $62.54 |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $30.87 | $1.57 |
| 52 Week High | $68.02 | $9.75 |
| Indicator | GRC | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 36.01 |
| Support Level | $56.98 | $4.07 |
| Resistance Level | $67.61 | $5.55 |
| Average True Range (ATR) | 2.36 | 0.21 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 51.50 | 17.99 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.